Home » Market News » DirectorsTalk Highlights » How up to one in five prostate cancer victims may have a genetic defect which triples their risk of death
Oxford BioDynamics

How up to one in five prostate cancer victims may have a genetic defect which triples their risk of death

Men with prostate cancer are three times more likely to die from it if they have a particular genetic mutation.

Up to one in five patients may have a genetic quirk which worsens their chances of survival and makes them more likely to relapse.

Most men with prostate cancer do not die from it, but scientists sought to find those with advanced cancer who were at greatest risk. In a study of 429 men at this stage of cancer, they found those with a mutated gene called RB1 in their tumour were 3.3 times more likely to die.

Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer and other diseases including ALS.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.